Biomarkers for rheumatoid arthritis and usage thereof

Patent metadata

Field	Value
Publication number	US-10883146-B2
Application number	US-201515515367-A
Country	US
Kind code	B2
Filing date	Jul 7, 2015
Priority date	Sep 30, 2014
Publication date	Jan 5, 2021
Grant date	Jan 5, 2021

Abstract

Biomarkers and methods for predicting risk of a disease in particular RA are provided. Sequences of DNA are obtained. The DNA may be extracted from a sample that is collected from a subject. A relative abundance of a biomarker is then calculated based on the sequences of the DNA. The biomarker comprises a DNA sequence in a genome of Lactobacillus salivarius . A probability of the subject having the disease is obtained based on the relative abundance.

First claim

What is claimed is:

1. A method for obtaining a probability of a subject having a disease wherein the disease is rheumatoid arthritis, comprising:
obtaining sequences of DNA extracted from a sample that is collected from the subject, wherein the sample comprises at least one of a fecal sample, a dental sample, and a salivary sample;
calculating a relative abundance of a biomarker based on the sequences of the DNA, wherein the biomarker comprises a DNA sequence in a genome of Lactobacillus salivarius ; and
obtaining a probability of the subject having the disease based on the relative abundance to thereby determine that the individual has the rheumatoid arthritis,
wherein the biomarker comprises at least one of the following metagenomic linkage groups (MLGs);
the MLG corresponding to the fecal sample that consists of MLG ID NO: 2169;
the MLG corresponding to the dental sample that consists of MLG ID NO: 16600; and
the MLG corresponding to the salivary sample that consists of MLG ID NO: 4643;
and wherein:
the MLG ID NO: 2169 consists of SEQ ID NOs: 1-593;
the MLG ID NO: 16600 consists of SEQ ID NOs: 594-1536; and
the MLG ID NO: 4643 consist of SEQ ID NOs: 1537-259, the method further comprising administering to the individual at least one disease-modifying antirheumatic drug (DMARD) to treat said rheumatoid arthritis.

2. The method of claim 1 , wherein the DMARD is selected from methotrexate (MTX), Tripterygium wilfordii (thunder god vine) Leflunomide, prednisolone, hydroxychloroquine, and etanercept.

3. The method of claim 2 , wherein the DMARD is methotrexate.

Assignees

• Bgi Shenzhen

Inventors

• Feng Qiang
• Zhang Dongya
• Jia Huijue
• Wang Donghui
• Wang Jun

Classifications

• C12Q2600/158

  Expression markers · CPC title

• C07K14/335

  from Lactobacillus (G) · CPC title

• A61K35/747 Primary

  Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title

• C12Q1/689 Primary

  for bacteria · CPC title

• C12Q2600/106

  Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism · CPC title